Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of.
At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics. As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality. To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude. The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions. We are seeking an experienced and strategic Associate Director/Director of Pharmacovigilance Operations to lead and evolve our global PV operational infrastructure. This is a high-impact role for someone with strong operational acumen and experience managing outsourced PV models in a biotech or fast-paced pharma environment. This role is accountable for the oversight of all outsourced safety operations, vendor governance, and operational compliance across clinical and post-marketing settings. The Associate Director/Director, PV Operations will play a critical role in scaling PV operations capabilities, ensuring inspection readiness, regulatory compliance, and contributing to strategic safety planning as the company transitions through late-phase development and into commercialization. The ideal candidate has experience supporting both clinical and post-marketing programs and can lead vendor governance, inspection readiness, and PV systems management. This role will support the Pharmacovigilance department and report to the Executive Director of Pharmacovigilance and Drug safety. Key responsibilities of the role include, but not limited to: JOB FUNCTION:
Job Requirements
The base range for an Associate Director is $169,000 - $203,000 and a Director is $218,000 - $255,000 per year. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus.
The Kura Package
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of small molecule drug candidates designed to target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration ("FDA") for the treatment of relapsed/refractory ("R/R") NPM1-mutant acute myeloid leukemia ("AML"). In November 2024, Kura Oncology entered into a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed, and in the second quarter of 2025, the companies announced the FDA's acceptance of a New Drug Application for ziftomenib for the treatment of adult patients with R/R NPM1-mutant AML and assignment of a Prescription Drug User Fee Act target action date of November 30, 2025. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies for patients with various solid tumors. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura's website at and follow us on X and LinkedIn.
...Swing Schedule 26ft Box Truck Delivery Driver w/Liftgate (driving, loading and unloading experience required). Great Pay! Serious Applicants ONLY!! Arnett Logistics Group LLC is growing, and we have opportunities for Independent Contractors who are reliable...
...Occasional travel in the US Secret or Top Secret clearance preferred US Citizenship required ~ Prior experience as a DHS Federal Employee a plus ~ DHS EoD a plus GDIT IS YOUR PLACE: Full-flex work week to own your priorities at work and at home...
...commitment to customer service and quality is expected. You will report to the Plasma Center Manager and will perform as a plasma donor screener and perform phlebotomy to support plasma center operations. How you will contribute: You will answer phones, and...
...individuals, regardless of demographic or other background, are encouraged to apply. Further, as a federal, state, and local contractor, we comply with government regulations and executive orders as applicable, including affirmative action responsibilities for qualified...
Dental Business Assistant Location Columbia City, IN : Columbia City Dentists, owned by Dr. Geoffrey Glogas, is looking for a friendly, motivated, and professional Business Assistant. The Dental Business Assistant will be responsible for all front office responsibilities...